Abstract Number: 0293 • ACR Convergence 2020
Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus
Background/Purpose: Anti-Ro autoantibody production often precedes the development of systemic lupus erythematosus (SLE) or Sjögren’s syndrome (SS) by years. Anti-Ro+ mothers of children with manifestations…Abstract Number: 1255 • ACR Convergence 2020
Sjӧgren’s Syndrome Minor Salivary Gland Mesenchymal Stromal Cells Derived Deploy Intact Immune Plasticity and Display Myofibroblast-Like Properties
Background/Purpose: Primary Sjӧgren’s syndrome (pSS) is the second most common systemic autoimmune disease with hallmark features of severe ocular and oral sicca, leading to reduced…Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…Abstract Number: 1256 • ACR Convergence 2020
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis in…Abstract Number: 0997 • ACR Convergence 2020
Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…Abstract Number: 1409 • ACR Convergence 2020
Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…Abstract Number: 1242 • ACR Convergence 2020
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…Abstract Number: 1502 • ACR Convergence 2020
Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)
Background/Purpose: Several recent randomized controlled trials that used the validated ESSDAI as primary endpoint failed, partly explained by relatively large response rates in the placebo…Abstract Number: 1243 • ACR Convergence 2020
Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
Background/Purpose: Fatigue is a major complaint in autoimmune diseases including primary Sjögren’s syndrome (pSS). For many pSS patients, fatigue is their most dominant and disabling…Abstract Number: 1503 • ACR Convergence 2020
Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands Might Help to Avoid Unnecessary Lip Biopsy in Patients with Sicca Syndrome
Background/Purpose: Major salivary gland ultrasonography (SGUS) has an established role as a first-line imaging tool in the diagnosis of primary Sjögren’s syndrome (pSS). Nowadays, however,…Abstract Number: 1244 • ACR Convergence 2020
Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…Abstract Number: 1504 • ACR Convergence 2020
Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
Background/Purpose: Relief of symptoms is a sine qua non for successful drug development in Sjӧgren’s syndrome (SS). However, symptom-based patient experience is understudied, particularly how…Abstract Number: 1245 • ACR Convergence 2020
Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients
Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of…Abstract Number: 1505 • ACR Convergence 2020
Antibodies Binding Ro/SSA and Muscarinic 3 Receptor in Sjogren’s Syndrome
Background/Purpose: Sjögren’s syndrome is characterized by exocrine gland dysfunction and autoantibody production. Some data suggest autoantibodies binding the muscarinic 3 receptor (M3R) mediate poor function…Abstract Number: 1246 • ACR Convergence 2020
Sjogren’s Syndrome and Its Risk of Cervical Lesions
Background/Purpose: Sjogren’s syndrome is chronic inflammatory disease that results in lacrimal and salivary dysfunction and can include extra-glandular manifestations. While it is well established that…
ACR Meeting Abstracts